BJMO - volume 16, issue 7, november 2022
I. Joye MD, PhD, S. Vanderkam MD, N. Meireson MD, R. Weytjens MD
Treatment of pancreatic ductal adenocarcinoma (PDAC) has been the subject of controversy for decades. At the centre of this controversy is radiation therapy. Since PDAC is considered a systemic disease, the role of radiation therapy is debated. However, most of the available evidence is blurred by suboptimal radiation doses, less effective chemotherapy regimens and abandoned radiotherapy techniques. This article reviewed the available literature and discussed the changes in radiation therapy that have taken place over the past decade.
(BELG J MED ONCOL 2022;16(7):328–35)
Read moreBJMO - volume 14, issue 6, october 2020
I. Joye MD, PhD, S. Vanderkam MD, N. Meireson MD, R. Weytjens MD
The treatment for locally advanced rectal cancer involves a multidisciplinary approach in which total mesorectal excision usually is preceeded by (chemo)radiotherapy. Depending on risk factors, adjuvant chemotherapy is frequently applied. Preoperative short course radiotherapy and chemoradiotherapy result in high local control rates. However, the high risk on systemic relapse and the appealing concept of organ preservation urge researchers to explore alternative perioperative strategies. This review provides an overview of the established role of preoperative short course radiotherapy and chemoradiotherapy, as well as the evidence so far for short course radiotherapy with delayed surgery, induction chemotherapy and for neoadjuvant chemotherapy without radiotherapy.
(BELG J MED ONCOL 2020;14(6):254-62)
Read moreBJMO - volume 14, issue 4, june 2020
M. Machiels MD, PhD, D. Nevens MD, PhD, K. Erven MD, PhD, G. Buelens MD, C. Billiet MD, PhD, Y. Geussens MD, P. Janssens MD, S. Vanderkam MD, R. Weytjens MD
Whole-breast irradiation, as part of breast-conservation therapy (BCT), has been well-established the last decades. Nonetheless, most local recurrences found after BCT are within or close to the tumour bed. This led to the concept of partial breast irradiation (PBI), delivering the radiation dose to a decreased target volume, thereby lowering exposure to the organs at risk and hence potentially minimizing late adverse effects. This became increasingly important with growing survivorship of patients with early-stage breast cancer over the past decades and the consideration of late adverse effects is gaining more importance. In this review, we will present an overview of the current literature, techniques to deliver PBI and we try to establish whether there is a place for PBI in early-stage breast cancer treatment.
(BELG J MED ONCOL 2020;14(4):140–45)
Read more
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
